Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Inozyme Pharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 50
- +13 vs. Q4 2022
- Shares held
- 32.0M
- +3.04M (+10.5%) vs. Q4 2022
- Total value
- $183.4M
- +$153.0M (+503.5%) vs. Q4 2022
- New holders
- 18
- 18 more added
- Sold out
- 5
- 5 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 4,265,138 | $24.4M | 0.05% | +1,165,000+37.6% | Added |
| Sofinnova Investments, Inc. | 3,655,308 | $20.9M | 1.42% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,250,000 | $18.6M | 0.79% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 3,214,900 | $18.4M | 0.44% | +128,873+4.2% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 3,213,586 | $18.4M | 7.58% | +552,432+20.8% | Added |
| NEA Management Company, LLC | 2,437,689 | $14.0M | 0.97% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 1,781,858 | $10.2M | 2.21% | +156,800+9.6% | Added |
| Millennium Management LLC | 1,691,075 | $9.69M | 0.01% | +1,393,139+467.6% | Added |
| CHI Advisors LLC | 1,342,191 | $7.69M | 2.04% | −862,685−39.1% | Reduced |
| Vanguard Group Inc | 1,328,290 | $7.61M | 0.00% | −15,332−1.1% | Reduced |
| Citadel Advisors LLC | 793,823 | $4.55M | 0.00% | +793,823 | New |
| Affinity Asset Advisors, LLC | 751,796 | $4.31M | 1.66% | +251,796+50.4% | Added |
| FMR LLC | 702,996 | $4.03M | 0.00% | +702,996 | New |
| Samsara BioCapital, LLC | 504,407 | $2.89M | 0.60% | +504,407 | New |
| BlackRock Inc. | 451,193 | $2.59M | 0.00% | +24,969+5.9% | Added |
| Laurion Capital Management LP | 271,800 | $1.56M | 0.07% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 241,208 | $1.38M | 0.00% | +8,082+3.5% | Added |
| MPM Oncology Impact Management LP | 233,728 | $1.34M | 0.35% | +3,228+1.4% | Added |
| Overbrook Management Corp | 219,326 | $1.26M | 0.33% | 00.0% | Unchanged |
| Marshall Wace, LLP | 195,097 | $1.12M | 0.00% | +195,097 | New |
| Renaissance Technologies LLC | 186,100 | $1.07M | 0.00% | −72,800−28.1% | Reduced |
| Knott David M Jr | 160,000 | $917.0K | 0.39% | +160,000 | New |
| UBS Oconnor LLC | 147,654 | $846.1K | 0.02% | +147,654 | New |
| Parkman Healthcare Partners LLC | 125,000 | $716.3K | 0.16% | +125,000 | New |
| Bridgeway Capital Management, LLC | 117,400 | $672.7K | 0.02% | −16,000−12.0% | Reduced |
| State Street Corp | 98,055 | $561.9K | 0.00% | +21,700+28.4% | Added |
| Two Sigma Investments, LP | 65,500 | $375.3K | 0.00% | +53,117+429.0% | Added |
| BIT Capital GmbH | 54,226 | $310.7K | 0.05% | +54,226 | New |
| Jane Street Group, LLC | 53,525 | $306.7K | 0.00% | +53,525 | New |
| Cubist Systematic Strategies, LLC | 50,712 | $290.6K | 0.00% | +50,712 | New |
| Dimensional Fund Advisors LP | 50,577 | $287.0K | 0.00% | +28,370+127.8% | Added |
| Bank of New York Mellon Corp | 47,165 | $270.3K | 0.00% | +26,922+133.0% | Added |
| Virtu Financial LLC | 46,995 | $269.0K | 0.03% | +46,995 | New |
| Northern Trust Corp | 45,882 | $262.9K | 0.00% | −61−0.1% | Reduced |
| HRT Financial LP | 45,114 | $258.0K | 0.00% | +45,114 | New |
| Schonfeld Strategic Advisors LLC | 28,600 | $163.9K | 0.00% | +28,600 | New |
| Man Group plc | – | $137.2K | 0.00% | – | New |
| Verition Fund Management LLC | 23,900 | $136.9K | 0.00% | +23,900 | New |
| Parallel Advisors, LLC | 19,867 | $113.8K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 19,356 | $110.9K | 0.00% | +6,210+47.2% | Added |
| Charles Schwab Investment Management Inc | 16,549 | $94.8K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 14,093 | $81.0K | 0.00% | +10,495+291.7% | Added |
| Bank of America Corp | 11,548 | $66.2K | 0.00% | +4,443+62.5% | Added |
| Barclays PLC | 6,273 | $35.9K | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 4,181 | $23.0K | 0.00% | +4,044+2,951.8% | Added |
| Point72 Middle East FZE | 1,897 | $10.9K | 0.00% | +1,897 | New |
| Group One Trading, L.P. | 626 | $3.59K | 0.00% | +626 | New |
| Wells Fargo & Company | 165 | $945 | 0.00% | +3+1.9% | Added |
| Point72 Asset Management, L.P. | 138 | $791 | 0.00% | +138 | New |
| JPMorgan Chase & Co | 60 | $0 | 0.00% | 00.0% | Unchanged |
| VR Adviser, LLC | 0 | $0 | 0.00% | −2,709,987−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −37,700−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −11,924−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,834−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −1,381−100.0% | Sold out |